TJ-100

PreclinicalSmall molecule

SShowa Inan General Hospital

TJ-100 is one of 24 small molecule programs targeting Chronic constipation. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic ConstipationActive, not recruiting

Chronic ConstipationPreclinical

Active, not recruiting

Competition

Competitive Landscape

40 competitors in Chronic Constipation

#DrugCompanyPhaseTrials

Resotran

Takeda

Approved

17 2

Golytely

Bayer

Approved

1 3

Linzess

AbbVie

Phase 3

3 4

Zelnorm

AAlfasigma S.p.A.

Phase 3

5 5

Chronulac

SSolvay Pharmaceuticals

Phase 3

2 6

Lactobacillus Reuteri

TTulane University School of Medicine

Phase 3

1 7

Amitiza

SSucampo Pharma Americas, LLC

Phase 2

4 8

Elobixibat

Ferring

Approved

3 9

Macrogol 4000

IIstituto Clinico Humanitas

Approved

1 10

Polyethyleneglycol3350

BBraintree Laboratories

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic constipation1 trial

Efficacy and Safety of TJ-100 in the Treatment of Chronic Constipation

Completed·SShowa Inan General Hospital·N/A·NCT00522093·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TJ-100. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TJ-100 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TJ-100. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Showa Inan General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SShowa Inan General Hospital

TJ-100

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic constipation1 trial

References

Drug Info

Quick Facts

Related News